AI tool to guide chemotherapy for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study tests an artificial intelligence (AI) tool that helps doctors choose the best chemotherapy plan for people with triple-negative breast cancer before surgery. By analyzing your tumor tissue, the AI aims to guide treatment to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have triple-negative breast cancer that has not spread to other parts of the body.
- You are scheduled to receive chemotherapy before your surgery (called neo-adjuvant therapy).
- You agree to donate a small tumor tissue sample for research (this is optional but required for the study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
This study tests whether an AI tool can predict how well breast cancer responds to chemotherapy given before surgery. Your tumor sample from a needle biopsy will be analyzed to see if the AI's prediction matches your actual treatment outcome.
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
This trial tests whether an artificial intelligence (AI) tool can help doctors plan radiation therapy more precisely for breast cancer. It aims to make treatment safer and more effective by using AI to outline the area to be treated.
This study tests an AI system that helps doctors classify breast biopsy results more accurately. It may lead to better treatment decisions for patients with breast abnormalities.
This trial tests an AI tool that predicts genetic risk for breast cancer. It may help women identified as high-risk by their breast surgeon get quicker genetic counseling.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.